---
title: "Kiora Pharmaceuticals reports Q2 2026 net loss of $2.08M, cash and short-term investments $16.8M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295225697.md"
description: "Kiora Pharmaceuticals reported a Q2 2026 net loss of $2.08M, with cash and short-term investments totaling $16.8M. R&D expenses were $2.08M before collaboration reimbursements. The company advanced Phase 2 trials for KIO-301 and KIO-104 and secured a private placement for up to $24.0M, receiving $5.0M upfront. Proceeds will support operations and potential strategic transactions."
datetime: "2026-08-07T11:13:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295225697.md)
  - [en](https://longbridge.com/en/news/295225697.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295225697.md)
generator: "portal-rs"
---

# Kiora Pharmaceuticals reports Q2 2026 net loss of $2.08M, cash and short-term investments $16.8M

Kiora Pharmaceuticals reported a net loss of $2.08 million for the quarter ended June 30, 2026, and ended the period with approximately $16.8 million in cash and short-term investments. The company said R&D expenses were $2.08 million for the quarter before $1.34 million in collaboration reimbursements and that collaboration receivables and other receivables totaled about $2.9 million. Kiora also disclosed ongoing Phase 2 enrollment for KIO-301 and KIO-104 and a private placement for up to $24.0 million, including $5.0 million received upfront.

**Financial Highlights**

-   Net loss for the three months ended June 30, 2026: $2,079,010.
-   Operating loss for the quarter: $2,213,771.
-   Cash and short-term investments at June 30, 2026: approximately $16.8 million (Cash $7,076,533; Short-term investments $9,761,994).
-   Research and development expense for the quarter: $2,077,116, before recognizing $1,336,263 in collaboration credits.
-   General and administrative expense for the quarter: $1,383,504.

**Business Highlights**

-   Advanced enrollment in the Phase 2 ABACUS-2 trial for KIO-301, including initiation of the higher 100 µg dose cohort; an independent predefined safety review will follow treatment of initial higher-dose patients.
-   Continued enrollment in the higher-dose cohort of the Phase 2 KLARITY trial for KIO-104, with initial clinical data expected in late 2026 to assess activity across inflammatory retinal conditions with macular edema.
-   Collaboration structure: Théa Open Innovation is fully reimbursing KIO-301 development costs under their license for U.S., Europe and other select countries outside Asia; Senju holds options in Japan, China and select Asian territories.
-   Secured a private placement for up to $24.0 million in gross proceeds, with $5.0 million received upfront and remaining proceeds contingent on exercise of milestone-based warrants; company said proceeds support operations and potential strategic activity.
-   Management pursuing potential strategic transactions to diversify and expand the pipeline and preparing personnel and operating capabilities to move quickly if a transaction completes.

Original SEC Filing: KIORA PHARMACEUTICALS INC \[ KPRX \] - 8-K - Aug. 07, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [KPRX.US](https://longbridge.com/en/quote/KPRX.US.md)

## Related News & Research

- [AgroGalaxy delays 2025 results release to Nov. 30, 2026](https://longbridge.com/en/news/297440664.md)
- [Citigroup announces Q3 2026 distribution of R$ 0.39 per unit, payable Sept. 3](https://longbridge.com/en/news/297699755.md)
- [Gaming and Leisure Properties declares Q3 2026 dividend of $0.82 per share](https://longbridge.com/en/news/297652371.md)
- [Jefferies declares Q3 2026 distribution of R$ 1.4 per unit, payable Sept. 3](https://longbridge.com/en/news/297683771.md)
- [Enjoei updates financial events calendar for 2026](https://longbridge.com/en/news/297563694.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**